Your browser doesn't support javascript.
loading
A Case of Cutaneous Plasmacytoma Treated with Thalidomide / 대한피부과학회지
Korean Journal of Dermatology ; : 1325-1328, 2004.
Article in Korean | WPRIM | ID: wpr-109650
ABSTRACT
Cutaneous involvement has been reported in all types of malignant plasma cell disorders including multiple myeloma, solitary myeloma of bone, plasma cell leukemia, and extramedullary plasmacytoma. But metastatic plasmacytomas in the skin are rare in multiple myeloma and extramedullary plasmacytoma. If skin tumors appear during the course of multiple myeloma, these should be interpreted as a sign of poor prognosis. Treatment of patients with resistant multiple myeloma is challenging. Thalidomide has recently shown antitumor activity in patients with refractory myeloma. Until the introduction of thalidomide, no drugs other than cytotoxic agents and glucocorticoids had shown antitumor activity to cutaneous plasmacytoma. We recently performed a clinicopathologic study of a patient with cutaneous involvement of multiple myeloma and reported our result with thalidomide therapy in this patient.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Plasma Cells / Plasmacytoma / Prognosis / Skin / Thalidomide / Leukemia, Plasma Cell / Cytotoxins / Glucocorticoids / Multiple Myeloma Type of study: Prognostic study Limits: Humans Language: Korean Journal: Korean Journal of Dermatology Year: 2004 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Plasma Cells / Plasmacytoma / Prognosis / Skin / Thalidomide / Leukemia, Plasma Cell / Cytotoxins / Glucocorticoids / Multiple Myeloma Type of study: Prognostic study Limits: Humans Language: Korean Journal: Korean Journal of Dermatology Year: 2004 Type: Article